VRDN Q4 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000-31.4% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$71M-99275.0% margin

Net Income

-$67M-92861.1% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$490M

Total Liabilities

$48M

Stockholders' Equity

$442M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$105,000	-31.4%
Gross Profit	$72,000	-$39M	+100.2%
Operating Income	-$71M	-$49M	-45.7%
Net Income	-$67M	-$46M	-46.0%